JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

Начало・Списък с акции・CytoSorbents Corp

CytoSorbents Corp

Затворен

СекторЗдравеопазване

0.66 1.54

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.65

Максимум

0.68

Ключови измерители
By Trading Economics
Приходи	-5.1M -3.2M
Продажби	-132K 9.5M
EPS	-0.05
Марж на печалбата	-33.421
Служители	149
EBITDA	-5.9M -2.9M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+11.94% upside

Дивиденти
By Dow Jones
Следващи печалби	11.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-2.8M 42M
Предишно отваряне	-0.88
Предишно затваряне	0.66

Настроения в новините

By Acuity

50%

144 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

0.705 / 0.771 Подкрепа & съпротива

CytoSorbents Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.02.2026 г., 17:25 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

9.02.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

9.02.2026 г., 23:43 ч. UTC

Пазарно говорене

Gold Falls on Possible Technical Correction -- Market Talk

9.02.2026 г., 23:14 ч. UTC

Пазарно говорене

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

9.02.2026 г., 22:29 ч. UTC

Пазарно говорене

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

9.02.2026 г., 22:19 ч. UTC

Пазарно говорене

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

9.02.2026 г., 22:08 ч. UTC

Пазарно говорене

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

9.02.2026 г., 22:01 ч. UTC

Печалби

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

9.02.2026 г., 21:59 ч. UTC

Печалби

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

9.02.2026 г., 21:59 ч. UTC

Печалби

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

9.02.2026 г., 21:58 ч. UTC

Печалби

Friedman Industries 3Q Sales $168M >FRD

9.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

9.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.02.2026 г., 21:48 ч. UTC

Печалби

Friedman Industries 3Q EPS 43c >FRD

9.02.2026 г., 21:17 ч. UTC

Печалби

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

9.02.2026 г., 21:13 ч. UTC

Пазарно говорене

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

9.02.2026 г., 21:04 ч. UTC

Печалби

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

9.02.2026 г., 20:30 ч. UTC

Пазарно говорене

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

9.02.2026 г., 20:02 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

9.02.2026 г., 19:42 ч. UTC

Пазарно говорене

Japan's Yield Curve Expected to Flatten -- Market Talk

9.02.2026 г., 19:31 ч. UTC

Пазарно говорене

Nike Seen Regaining Relevance With Consumers -- Market Talk

9.02.2026 г., 19:27 ч. UTC

Пазарно говорене

Gold Climbs Back Over $5,000/oz -- Market Talk

9.02.2026 г., 19:05 ч. UTC

Пазарно говорене

Nike Returns to List of Hottest Brands -- Market Talk

9.02.2026 г., 18:19 ч. UTC

Пазарно говорене

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

9.02.2026 г., 17:41 ч. UTC

Печалби

Придобивния, сливания и поглъщания

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

9.02.2026 г., 17:31 ч. UTC

Печалби

Придобивния, сливания и поглъщания

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

9.02.2026 г., 17:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

9.02.2026 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.02.2026 г., 17:17 ч. UTC

Пазарно говорене

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

9.02.2026 г., 17:16 ч. UTC

Печалби

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

CytoSorbents Corp Прогноза

Ценова цел

By TipRanks

11.94% нагоре

12-месечна прогноза

Среден 0.75 USD 11.94%

Висок 0.75 USD

Нисък 0.75 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за CytoSorbents Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на CytoSorbents Corp през последните 3 месеца.

Техническа оценка

By Trading Central

0.705 / 0.771Подкрепа & съпротива

All events are bearish.

Настроение

By Acuity

144 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.